RxDoctor Payments DataLook up a doctor →

Michelle Terwilliger, NP

Family · Dyer, INNPI 1912360546

Payments from drug & device makers

$15,612in general payments, 2019–2025

Across 886 payments — averaging $17.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$3K
  • AbbVie$2K
  • Lilly USA, LLC$820
  • AstraZeneca$749
  • Bristol Myers Squibb$498
  • Eisai Inc.$443
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$15,50199%
  • Education$1111%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biogen161$3,132
AbbVie(2 entities)153$1,964
Lilly USA, LLC41$820
AstraZeneca(2 entities)33$749
Bristol Myers Squibb32$498
Eisai Inc.23$443
Catalyst Pharmaceuticals, Inc.19$438
Teva Pharmaceuticals USA, Inc.27$429
Novartis33$423
EMD Serono, Inc.24$396
Argenx US, Inc.18$352
Pfizer40$347
UCB, Inc.18$337
SK Life Science, Inc.12$284
Jazz Pharmaceuticals Inc.12$275
Neurelis, Inc.7$271
Neurocrine Biosciences, Inc.10$253
Johnson & Johnson13$248
Banner Life Sciences, LLC15$240
Mallinckrodt Hospital Products Inc.10$240
Lundbeck LLC9$224
Acorda Therapeutics, Inc10$211
Sanofi10$194
CSL Behring8$162
Genentech USA, Inc.7$161
Sunovion Pharmaceuticals Inc.12$158
MDD US Operations, LLC8$157
Corium, LLC13$143
Amneal Pharmaceuticals LLC8$143
Merz Pharmaceuticals, LLC5$139
GRT US Holding, Inc.2$125
Amgen6$122
Collegium Pharmaceutical, Inc.7$122
Acadia Pharmaceuticals Inc7$118
TG Therapeutics, Inc.4$97
Grifols USA, LLC4$86
Alnylam Pharmaceuticals Inc.4$82
Livanova USA, Inc.5$81
Supernus Pharmaceuticals, Inc.4$78
Takeda Pharmaceuticals U.S.A., Inc.4$76
Upsher-smith Laboratories LLC5$71
Sumitomo Pharma America, Inc.5$69
Harmony Biosciences LLC3$54
E.r. Squibb & Sons, L.L.C.3$50
Abbott3$48
Biohaven Pharmaceuticals, Inc.3$47
Avanir Pharmaceuticals, Inc.3$46
Biohaven Pharmaceutical Holding Company Ltd.3$44
Revance Therapeutics, Inc.1$37
Ipsen Biopharmaceuticals, Inc1$33
Almatica Pharma LLC2$30
Azurity Pharmaceuticals, Inc.2$30
Cycle Pharmaceuticals Inc1$27
Vanda Pharmaceuticals Inc.2$25
Octapharma USA, Inc.1$23
Bioventus LLC1$22
Scilex Pharmaceuticals Inc.1$22
Impel Pharmaceuticals Inc.1$18
Impel Pharmaceuticals LLC1$17
Boston Scientific1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,612 in reported general payments places this provider in the 95th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$49,531
Medicare patients
192
Services billed
1,637

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BetaseronInterferon Beta-1b13$125,275
TecfideraDimethyl Fumarate12$113,914
Nurtec OdtRimegepant Sulfate93$102,484
QuliptaAtogepant72$92,279
FycompaPerampanel65$76,647
UbrelvyUbrogepant44$54,412
Emgality PenGalcanezumab-Gnlm62$45,746
Aimovig AutoinjectorErenumab-Aooe49$42,184
AptiomEslicarbazepine Acetate28$35,698
VimpatLacosamide24$28,469
XcopriCenobamate22$25,548
NuedextaDextromethorphan Hbr/Quinidine15$19,368
HorizantGabapentin Enacarbil15$15,436
TopamaxTopiramate11$15,414
Topiramate ErTopiramate19$14,032

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy$1,964$146,691116 claims
BiogenTecfidera$3,132$113,91412 claims
PfizerNurtec Odt$347$102,48493 claims
Eisai Inc.Fycompa$443$76,64765 claims
Sunovion Pharmaceuticals Inc.Aptiom$158$35,69828 claims
UCB, Inc.Vimpat$337$28,46924 claims
SK Life Science, Inc.Xcopri$284$25,54822 claims
Avanir Pharmaceuticals, Inc.Nuedexta$46$19,36815 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$78$8,32612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,392 family providers in Indiana.

Other family in Dyer

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →